Delivery Order SPE2DR25D1103-SPE2DR26FE345
- Not listed
- The Defense Logistics Agency awarded a $1,554.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for MYFEMBREE 40 MG-1 MG-0.5 MG tablets (28-count supply) on November 14, 2025, with completion targeted for November 17, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a $2,233.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for MYFEMBREE 40 MG-1 MG-0.5 MG tablets (28-count) with an ultimate completion date of June 2, 2025. This non-set-aside award was made competitively and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a $4,543.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for MYFEMBREE pharmaceutical products (40 mg, 1 mg, and 0.5 mg tablets in a 28-count package) on October 30, 2025, with an ultimate completion date of October 31, 2025. The contract was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a $1,497.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp for MYFEMBREE (a combined hormonal contraceptive tablet available in 40 mg, 1 mg, and 0.5 mg formulations, 28-count packaging) on December 4, 2025, with completion expected by December 5, 2025. This non-set-aside contract will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,597.46 to AmerisourceBergen Drug Corp for MYFEMBREE pharmaceutical products (40 mg, 1 mg, and 0.5 mg tablets in a 28-count package). This firm fixed-price, non-set-aside contract was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,899.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for MYFEMBREE pharmaceutical products (40 mg, 1 mg, and 0.5 mg tablets, 28-count package) with a completion date of December 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion and extending through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $2,991.21 to AmerisourceBergen Drug Corp for the supply of Myfembree (40 mg-1 mg-0.5 mg tablets, 28-count packages) on December 2, 2025, with completion scheduled for December 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Myfembree (40 mg, 1 mg, and 0.5 mg tablets) in a quantity of 28 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $2,149.77 and is scheduled for completion by September 9, 2025. The contract represents a non-set-aside procurement, indicating AmerisourceBergen's competitive selection among qualified vendors....
- The Defense Logistics Agency awarded a delivery order valued at $8,499.46 to AmerisourceBergen Drug Corp for the supply of Myfembree (40 mg, 1 mg, 0.5 mg tablets, 28-count package) on April 25, 2025, with an ultimate completion date of April 28, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,316.97 to AmerisourceBergen Drug Corp for pharmaceutical supplies, specifically Myfembree 40 mg, 1 mg, and 0.5 mg tablets in a 28-count package. The contract is a firm fixed price delivery order with no set-aside designation, issued on September 22, 2025, with an ultimate completion date of September 23, 2025. Performance will be executed at AmerisourceBergen's Conshohocken, Pennsylvania facility, which serves as the company's...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FE345Delivery Order
The Defense Logistics Agency awarded a $2,866.12 firm fixed price delivery order to AmerisourceBergen Drug Corp for MYFEMBREE 40 MG-1 MG-0.5 MG tablets (28-count package) on December 12, 2025, with completion scheduled for December 15, 2025. This non-set-aside contract represents a standard pharmaceutical supply transaction under the company's larger federal contracting relationship with DLA. The product will be performed and delivered from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The company's comprehensive federal contract portfolio encompasses a wide range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. DLA has indicated plans to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, with AmerisourceBergen positioned as a potential continued provider to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 12/11/25 |